Table 3.

Matched pair analysis comparing survival among patients who underwent allogeneic HSCT for first chronic phase chronic myeloid leukemia from 1999 to 2004

Variable	n	Relative risk of death (95% CI)	P
Main effect
No imatinib	236	1.00*
Imatinib	143	0.48 (0.31-0.75)	.001†

Matched variables include (1) time from diagnosis to transplant plus or minus 3 months, (2) HLA match, (3) graft type, and (4) sex match versus other. There are 143 imatinib cases for which matched controls were identified.

CI indicates confidence interval.

^*Reference group.

^†One degree of freedom.